All In Biotech

Drug Trial Radar · NCT00734123

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.

Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases.

Last checked: Nov 20, 2026Latest source record: Aug 14, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,948 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,948

Planned (sponsor's estimate)

Start

Apr 2008

Primary completion

Apr 2009

Study completion May 2013

Sponsor

Lead sponsor
Hospital Arnau de VilanovaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Aug 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 74 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The incidence of cardiovascular diseases is still high and further efforts should be done in primary prevention. The main objective is to quantify the burden of subclinical atherosclerosis using non-invasive techniques,and to study the impact of this assessment and consequent treatment in the progression of atherosclerosis and in the incidence of cardiovascular diseases.

Conditions

  • Atherosclerosis
  • Cardiovascular Diseases

Interventions

  • Simvastatin or AtorvastatinDrug

    Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.

  • EnalaprilDrug

    Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly

  • Aspirin or clopidogrelDrug

    Aspirin 100 mg or clopidogrel 75 mg/ per day

  • RimonabantDrug

    In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned. Drugs will be prescribed as the standard clinical care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Carotid Intima-Media Thickness progression/regressionTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Arnau de Vilanova

    Lleida, Catalonia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.